TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult ED

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* All patients age 18 or older who present to the ED with a complaint requiring antiemetic treatment who do not meet the exclusion criteria.~Exclusion Criteria:~* Patients less than 18 years of age~* Unstable patients with SBP \< 90~* Patients with a stated or documented allergy to any of the study medications~* Patients whose nausea rating if \< 40 on the pretreatment VAS scale~* Patients who have received a commonly accepted antiemetic within the previous 24 hours~* Patients unwilling or unable to complete the assessment tool before and 30 minutes after study drug dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ondansetron (Type: ACTIVE_COMPARATOR): Ondansetron 4 mg intravenous administration
- Metoclopramide (Type: ACTIVE_COMPARATOR): Metoclopramide 10 mg intravenous administration
- Promethazine (Type: ACTIVE_COMPARATOR): Promethazine 10 mg intravenous administration
- Saline Placebo (Type: PLACEBO_COMPARATOR): Volume-matched saline placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Birth weight less than 1200gm~* Less than 28 weeks gestational age~* Confirmed Patent Ductus Arteriosus (PDA) via echocardiogram and clinical exam~Exclusion Criteria:~* Active Bleeding~* Currently being treated for Persistent Pulmonary Hypertension (PPHN)~* Cardiac anomalies~* Chromosomal abnormalities~* Endocrine, metabolic, renal, or hepatic disorders

- Gender: ALL
- Minimum Age: None
- Maximum Age: 96 Hours
- Healthy Volunteers: f

Study Arms:
- Early treatment (Type: ACTIVE_COMPARATOR): Infants randomized to this group will receive their initial dose of ibuprofen prior to reaching 96 hrs old
- Late treatment (Type: ACTIVE_COMPARATOR): Infants randomized to this group will receive their initial dose of ibuprofen after infant has reached 96 hrs old but before the infant reaches 10 days old.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Zinc Sulfate in the Treatment of Rosacea: A Randomized, Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of facial rosacea made or confirmed by one of the investigators.~* Severity of signs of rosacea greater than mild at the time of enrollment.~Exclusion Criteria:~* Treatment for rosacea during the 3 months prior to enrollment.~* Use of zinc dietary supplement \> 25 mg per day during the 3 months prior to enrollment ( Most patients taking multivitamins with Zinc, often 15 mg per day, will not be excluded, whereas most patients taking additional Zinc supplements, often 25-50 mg per day or more will be excluded.)~* Diagnosis of rosacea fulminancy.~* Pregnant or breast feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Zinc sulfate (Type: EXPERIMENTAL): 220 mg of zinc sulfate
- Lactose (Type: PLACEBO_COMPARATOR): 270 mg lactose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Deficits, Adaptation and Cerebral Functional Reorganization of Visual Retinotopic Treatments During Normal and Pathological Aging (Age-related Macular Degeneration and Glaucoma)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy / control participants: normal or normal corrected visual acuity~* Patients with AMD: Diagnosis of AMD by the Clinique d'ophtalmologie of the CHU de Grenoble~* Patients Glaucoma: Diagnosis of glaucoma by the Clinique d'ophtalmologie of the CHU de Grenoble~* Affiliation to a social security scheme,~* Informed consent signed,~* Medical examination before participation in the MRI examination~Exclusion Criteria:~* Major unprotected persons unable to express their consent,~* Major protected,~* Significant hearing impairment,~* Neuropsychiatric pathology past or present (except benign epilepsy),~* Taking narcotics and / or drugs for neurocognitive purposes,~* Existence of a general ailment (cardiac, respiratory, haematological, renal, hepatic, cancer),~* Other ophthalmic pathology that can affect visual function: cataract, retinal detachment~* Contra-indication to MRI:~  1. Any subject with a vascular stent implanted less than 6 weeks before the examination.~ 2. Any subject carrying implanted biomedical material judged unsafe or unsafe in the list: http://www.mrisafety.com/TheList_search.asp.~ 3. Any acquisition procedure that does not comply with the conditions required by the conditional use in a subject carrying implanted biomedical material considered conditional in the list: http://www.mrisafety.com/TheList_search. Asp.~ 4. Any subject carrying an intra-ocular or intracranial ferromagnetic foreign body close to the nervous structures.~ 5. Any subject with biomedical equipment such as a cardiac, neuronal or sensory pacemaker (cochlear implant) or a ventricular bypass valve without medical and paramedical support trained to perform MRI in these subjects.~ 6. Non-Cooperative Subject~ 7. Metallic or electronic equipment incompatible with MRI examination, dental apparatus, claustrophobia, pacemaker or neurologic, non-magnetic non-magnetic vascular clip, metallic luster, diabetes~* Pregnant women~* Woman of childbearing age refusing to take the pregnancy test~* Ongoing drug treatment that may affect brain activity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cerebral Bases of Central and Peripheral Visual Integration (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dantrolene for Treatment of Hyperthermia in Subarachnoidal Hemorrhage (SAH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* neurosurgical patients after subarachnoidal hemorrhage~* breathing spontaneously or being ventilator dependant~* sustained fever (≥38ºC for more than an hour) without an identifiable infectious cause.~Exclusion Criteria:~* infection~* pregnancy~* arrhythmia~* muscular dystrophia~* acute liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dantrolene (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Dorsal Versus Volar Approach for CapFlex-PIP© Implantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Indication for CapFlex-PIP© arthroplasty~* Patient aged 18 years and over~* Informed Consent as documented by signature~Exclusion Criteria:~* Revision surgery~* CapFlex-PIP© arthroplasty at the thumb IP joint~* Major surgery at the same finger (e.g. DIP arthrodesis)~* Ulnar/radial deviation of the PIP joint \> 15°~* Patients in which a reconstruction of the collateral ligaments has to be performed~* General medical contraindication to surgery~* German language barrier to complete the questionnaires~* Any disease process that would preclude accurate evaluation (e.g. neuromuscular, psychiatric or metabolic disorder)~* Pregnancy~* Surgery not planned by Dr. Herren, Dr. Schindele or Dr. Bodmer~* Legal incompetence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dorsal approach CapFlex arthroplasty (Type: EXPERIMENTAL): Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the dorsal approach.
- Volar approach CapFlex arthroplasty (Type: ACTIVE_COMPARATOR): Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the volar approach.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 3D Ultrasound - Based Hysteroscopy Versus Virtual Hysteroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Diagnostic hysteroscopy prescribed either for a case of infertility or in case of doubt of endometrial / uterine pathology suspected by ultrasound or hysterography.~Exclusion Criteria:~* Current Pregnancy.~* Genital infection

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 3 dimensional sonohysterography (Type: ACTIVE_COMPARATOR): 3 dimensional sonohysterography
- Standard hysteroscopy (Type: ACTIVE_COMPARATOR): Standard hysteroscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Predictors and Prognostic Factors on the Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years old, of either sex~* Confirmation by CT scan~* Willingness to participate in the study and comply with its procedures by signing a written informed consent~Exclusion Criteria:~* Cerebral hemorrhagic infarction confirmed by CT scan~* Patients with severe systemic disease who are expected to survive for no more than three months~* Unwilling to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients With Ischemic Stroke (Type: None): The patients with all types of ischemic stroke including TIA, small vessle diseases, MCAO, and ect. These patients will be recorded their emergency treatment, medical history, details about their drug therapy, results of their routine blood test and image scan, and whether they receive intravascular therapy in time or not.
- Healthy Control (Type: None): The patients admitted to hospital for symptoms like dizzness and headache, which later proved to be not related to cerebral vascular diseases, would be treated as control. Their medical history and the results of their routine blood test and image scan will be recorded.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Quadratus Lumborum Block for Post-Cesarean Analgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Elective cesarean delivery~* American Society of Anesthesiologists Physical Status 1-3~* Suitable for procedure to be carried out under spinal anesthesia~Exclusion Criteria:~* Inability to give informed consent or to co-operate with post-operative evaluation~* Allergy to local anesthetics, morphine, fentanyl, ropivacaine~* Ongoing major medical or psychiatric problems~* Chronic opioid use~* Major coagulopathy~* BMI\>35 on first ante natal visit~* Pre-eclampsia~* Contraindication to neuraxial anesthesia

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: SHAM_COMPARATOR): Group 1 will receive intrathecal morphine co-administered with the spinal anesthetic. After the completion of surgery, bilateral ultrasound guided Sham Block be done with 25 mL of saline per side.
- Group 2 (Type: ACTIVE_COMPARATOR): Group 2 will receive an equivalent volume of intrathecal saline co-administered with the spinal anesthetic. After surgery, bilateral ultrasound guided Quadratus Lumborum Block will be performed with 25 ml 0.5% Ropivacaine per side.
- Group 3 (Type: ACTIVE_COMPARATOR): Group 3 will receive will receive intrathecal morphine with the spinal anesthetic. After the completion of surgery, bilateral ultrasound guided Quadratus Lumborum Block will be performed with 25 ml 0.5% Ropivacaine per side.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Herceptin in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must be female.~* Informed consent must be signed.~* Women with locally advanced breast cancers or primary breast cancers with concomitant gross metastatic disease are eligible. Locally advanced cancers must be of clinical and/or radiologic size \> 4 cm, and/or are deemed surgically inoperable.~* Her2/neu overexpressing tumors defined as HercepTest score of 3+, or \>/= one-third of invasive tumor showing membranous staining, or fluorescence in situ hybridization (FISH) positive.~* Negative serum pregnancy test (bHCG) within 7 days of starting study, if of child-bearing potential.~* Kidney and liver function tests - all within 1.5 times of the institution's upper limit of normal.~* Performance status (World Health Organization \[WHO\] scale) \< 2 and life expectancy \> 6 months.~* Age \> 18.~* No metastatic disease without concomitant primary breast cancer.~* No previous or current malignancies at other sites within the last 5 years, with exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.~Exclusion Criteria:~* Pregnancy or unwillingness to use a reliable contraceptive method in women of child-bearing potential.~* Severe underlying chronic illness or disease.~* Cardiomyopathy or baseline left ventricular ejection fraction (LVEF) \< 50%.~* Patients on other investigational drugs while on study.~* Severe or uncontrolled hypertension defined as blood pressure (BP) \> 180/100 on three separate occasions.~* History of congestive heart failure.~* History of coronary arterial disease.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Heceptin (Type: EXPERIMENTAL): Herceptin administered to enrolled subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intraoperative Fetal Heart Rate (FHR) Monitoring: a Feasibility Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. First 15 patients only- Elective induction of labor, not yet in active labor.~2. Subsequent 40 patients - Scheduled cesarean sections performed under spinal anesthesia~3. Patients ages 18-45~Exclusion Criteria:~1. Urgent or emergent cesarean sections~2. Cesarean sections performed under general anesthesia

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- intraoperative FHR monitoring (Type: None): Intraoperative fetal heart rate (FHR) monitoring

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Prenatal Steroids for Treatment of Congenital Cystic Adenomatoid Malformations (CCAM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* GA \< 26 weeks~* Maternal age \> 18 years of age~* Singleton pregnancy~* Normal chromosomes~* CCAM volume to head circumference ratio (CVR) \> 1.4~* No maternal medical/surgical contraindications~* No evidence of hydrops~* Not previously randomization~Exclusion Criteria:~* Maternal diabetes or use of insulin~* Preterm labor~* Multiple congenital anomalies with CCAM~* Chromosomal anomaly with CCAM~* Multiple gestation pregnancy with CCAM~* Not willing to be randomized~* Unable or unwilling to return to UCSF for second dose of drug or placebo~* CVR \< 1.4

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Active Study Group (Type: ACTIVE_COMPARATOR): STEROID: Betamethasone; 12 mg intramuscularly x 2 doses 24 hours apart
- Placebo Group (Type: PLACEBO_COMPARATOR): PLACEBO: IM x 2 doses 24 hours apart

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Diabetes-Obstructive Sleep Apnea Treatment Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Suboptimal glucose control (A1C ≥ 6.5%)~* Moderate-to-severe obstructive sleep apnea (apnea + hypopnea index \>= 10/hour)~* age 18 years and older~Exclusion Criteria:~* Poor glucose control (A1C \> 11)~* Type 1 or gestational diabetes~* Sleep duration \< 4 hrs~* Acute medical or surgical conditions or hospitalization ≤ 3 months~* Oxygen or bi-level PAP required~* Prior CPAP or persons in household with CPAP~* Employed in safety sensitive job~* Pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active CPAP treatment (Type: EXPERIMENTAL): Treatment of obstructive sleep apnea with continuous positive airway pressure (CPAP)
- Sham-CPAP (Type: PLACEBO_COMPARATOR): Device that appears like the treatment of obstructive sleep apnea, a continuous positive airway pressure device, but that does not provide treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dual Energy Computed Tomography (CT) in Finding Bone Metastases in Patients With Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients being imaged with PET/CT for diagnosis and/or staging of disease at Case Comprehensive Cancer Center~* Patients with bone metastases on PET/CT~* Patients without bone metastases on PET/CT~* All cancer types and both newly diagnosed and previously treated patients will be included~Exclusion Criteria:~* Patients with intervening treatment during the time between diagnostic CT and PET/CT~* Time between the diagnostic CT and PET/CT greater than 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (VNC DECT) (Type: None): Patients undergo CT scans. Additional images will be processed with virtual non-calcium (VNC) dual energy CT (DECT) information. Comparison will be made between images with and without addition of VNC.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of the Addition of Osmotic Dilators to Preparation Prior to Labor Induction Abortion

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Requesting abortion 19-23 weeks~* No contraindication to induction abortion~Exclusion Criteria:~* Fetal demise~* Ruptured membranes~* Evidence of pelvic infection~* Inability to give informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- osmotic dilator (Type: EXPERIMENTAL): osmotic dilator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Indirect Calorimetry: SensorMedics Vmax vs GE Carescape - a Method Comparison Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \< 18 years of age,~* endotracheally intubated.~* FiO2 \< 0,6, tube leak \< 10%, tidal volume \> 50 ml.~Exclusion Criteria:~* Ventilatory and hemodynamically unstable during 2 hours prior to inclusion.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy